U87 CAR-T cell therapy(Unicar-Therapy Bio-Medicine Technology)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameU87 CAR-T cell therapy(Unicar-Therapy Bio-Medicine Technology)
Drug Alias NameU-87
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocyte replacementsAnti-Trop-2
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsSolid tumoursLung NeoplasmsNasopharyngeal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesShanghai Youkadi Smart Life Technology Co Ltd
Active IndicationsSolid tumoursLung NeoplasmsNasopharyngeal Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A